Intranasal Insulin Transport is Preserved in Aged SAMP8 Mice and is Altered by Albumin and Insulin Receptor Inhibition

Journal of Alzheimer's Disease

Volumn 57, Issue 1, 2017, Pages 241-252

  Rhea, Elizabeth M ^a   Humann, Samantha R ^b   Nirkhe, Surabhi ^a   Farr, Susan A ^c,d   Morley, John E ^c   Banks, William A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; insulin; intranasal administration; pharmacokinetics

Indexed keywords

BOVINE SERUM ALBUMIN; INSULIN RECEPTOR; IODINE 125; PROTEIN INHIBITOR; RECOMBINANT HUMAN INSULIN; S 961; UNCLASSIFIED DRUG; ALBUMINOID; ANTIDIABETIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; INSULIN; PEPTIDE; RADIOACTIVE IODINE; RECOMBINANT PROTEIN; S961 PEPTIDE;

AGED; AGING; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN REGION; CD-1 MOUSE; CEREBELLUM; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE PREDISPOSITION; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG TRANSPORT; HIPPOCAMPUS; HYPOTHALAMUS; ISOTOPE LABELING; MALE; MESENCEPHALON; MOUSE; NONHUMAN; OLFACTORY BULB; PONS; PRIORITY JOURNAL; SENESCENCE ACCELERATED MOUSE; THALAMUS; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN; COHORT ANALYSIS; DISEASE MODEL; DRUG EFFECTS; HUMAN; INTRANASAL DRUG ADMINISTRATION; METABOLISM;

ADMINISTRATION, INTRANASAL; AGING; ALBUMINS; ALZHEIMER DISEASE; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; COHORT STUDIES; DISEASE MODELS, ANIMAL; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; IODINE RADIOISOTOPES; MALE; PEPTIDES; RECEPTOR, INSULIN; RECOMBINANT PROTEINS;

EID: 85015183743     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-161095     Document Type: Article

References (35)

1. de la Monte SM, Tong M (2014) Brain metabolic dysfunction at the core of Alzheimer's disease. Biochem Pharmacol 88, 548-559.
2. Blazquez E, Velazquez E, Hurtado-Carneiro V, Ruiz-Albusac JM (2014) Insulin in the brain: Its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front Endocrinol (Lausanne) 5, 161.
3. Cholerton B, Baker LD, Craft S (2011) Insulin resistance and pathological brain ageing. Diabet Med 28, 1463-1475.
4. Adzovic L, Lynn AE, D'Angelo HM, Crockett AM, Kaercher RM, Royer SE, Hopp SC, WenkGL (2015) Insulin improves memory and reduces chronic neuroinflammation in the hippocampus of young but not aged brains. J Neuroinflammation 12, 63.
5. Hanson LR, Frey WH (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 9 (Suppl 3) , S5.
6. Salameh TS, Bullock KM, Hujoel IA, Niehoff ML, Wolden-Hanson T, Kim J, Morley JE, Farr SA, Banks WA (2015) Central nervous system delivery of intranasal insulin: Mechanisms of uptake and effects on cognition. J Alzheimers Dis 47, 715-728.
7. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, KernW (2004) Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29, 1326-1334.
8. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial. Arch Neurol 69, 29-38.
9. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440-448.
10. Anderson KL, Frazier HN, Maimaiti S, Bakshi VV, Majeed ZR, Brewer LD, Porter NM, Lin AL, Thibault O (2016) Impact of single or repeated dose intranasal zinc-free insulin in young and aged F344 rats on cognition, signaling, and brain metabolism. J Gerontol A Biol Sci Med Sci 72, 189-197.
11. Maimaiti S, Anderson KL, DeMoll C, Brewer LD, Rauh BA, Gant JC, Blalock EM, Porter NM, Thibault O (2016) Intranasal insulin improves age-related cognitive deficits and reverses electrophysiological correlates of brain aging. J Gerontol A Biol Sci Med Sci 71, 30-39.
12. Lochhead JJ, Thorne RG (2012) Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 64, 614-628.
13. Lochhead JJ, Wolak DJ, PizzoME, ThorneRG (2015) Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J Cereb Blood Flow Metab 35, 371-381.
14. Banks WA, Farr SA, Morley JE (2000) Permeability of the blood-brain barrier to albumin and insulin in the young and aged SAMP8 mouse. J Gerontol A Biol Sci Med Sci 55, B601-B606.
15. Morley JE, Farr SA, Kumar VB, Armbrecht HJ (2012) The SAMP8 mouse: A model to develop therapeutic interventions for Alzheimer's disease. Curr Pharm Des 18, 1123-1130.
16. Schaffer L, Brand CL, Hansen BF, Ribel U, Shaw AC, Slaaby R, Sturis J (2008) A novel high-affinity peptide antagonist to the insulin receptor. Biochem Biophys Res Commun 376, 380-383.
17. Glowinski J, Iversen LL (1966) Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem 13, 655-669.
18. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd (2004) Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481-496.
19. BanksWA, Kumar VB, Farr SA, Nakaoke R, Robinson SM, Morley JE (2011) Impairments in brain-to-blood transport of amyloid-beta and reabsorption of cerebrospinal fluid in an animal model of Alzheimer's disease are reversed by antisense directed against amyloid-beta protein precursor. J Alzheimers Dis 23, 599-605.
20. Silverberg GD, Levinthal E, Sullivan EV, Bloch DA, Chang SD, Leverenz J, Flitman S, Winn R, Marciano F, Saul T, Huhn S, Mayo M, McGuire D (2002) Assessment of lowflow CSF drainage as a treatment for AD: Results of a randomized pilot study. Neurology 59, 1139-1145.
21. May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI (1990) Cerebrospinal fluid production is reduced in healthy aging. Neurology 40, 500-503.
22. Werner H, LeRoithD (2014) Insulin and insulin-like growth factor receptors in the brain: Physiological and pathological aspects. Eur Neuropsychopharmacol 24, 1947-1953.
23. Havrankova J, Roth J, Brownstein M (1978) Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272, 827-829.
24. Unger JW, Livingston JN, Moss AM (1991) Insulin receptors in the central nervous system: Localization, signalling mechanisms and functional aspects. Prog Neurobiol 36, 343-362.
25. Banks WA, Jaspan JB, Huang W, Kastin AJ (1997) Transport of insulin across the blood-brain barrier: Saturability at euglycemic doses of insulin. Peptides 18, 1423-1429.
26. Falcone JA, Salameh TS, Yi X, Cordy BJ, Mortell WG, Kabanov AV, Banks WA (2014) Intranasal administration as a route for drug delivery to the brain: Evidence for a unique pathway for albumin. J Pharmacol Exp Ther 351, 54-60.
27. Kratz F, Elsadek B (2012) Clinical impact of serum proteins on drug delivery. J Control Release 161, 429-445.
28. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, Markussen J (1995) Albumin binding of insulins acylated with fatty acids: Characterization of the ligandprotein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 312 (Pt 3) , 725-731.
29. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM (1996) Leptin enters the brain by a saturable system independent of insulin. Peptides 17, 305-311.
30. Elsadek B, Kratz F (2012) Impact of albumin on drug delivery-newapplications on the horizon. J Control Release 157, 4-28.
31. King GL, Johnson SM (1985) Receptor-mediated transport of insulin across endothelial cells. Science 227, 1583-1586.
32. Duffy KR, Pardridge WM (1987) Blood-brain-barrier transcytosis of insulin in developing rabbits. Brain Res 420, 32-38.
33. Bollag GE, Roth RA, Beaudoin J, Mochlyrosen D, Koshland DE (1986) Protein-kinase-C directly phosphorylates the insulin-receptor in vitro and reduces its protein-tyrosine kinase-activity. Proc Natl Acad Sci U S A 83, 5822-5824.
34. Naruse K, Rask-Madsen C, Takahara N, Ha SW, Suzuma K, Way KJ, Jacobs JR, Clermont AC, Ueki K, Ohshiro Y, Zhang J, Goldfine AB, King GL (2006) Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes 55, 691-698.
35. Chen Y, Zhao Y, Dai CL, Liang Z, Run X, Iqbal K, Liu F, Gong CX (2014) Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Abeta level and microglia activation in the brains of 3xTg-AD mice. Exp Neurol 261, 610-619.